Cathie Wood Doubles Down On Telehealth Play With $15M Buy
Cathie Wood-led Ark Investment Management on Thursday bought the dip in shares of telehealth services provider Teladoc Health, Inc. (NYSE: TDOC).
Recap Of Thursday’s Biotech Catalysts – End of The Day Summary
Cyclerion Therapeutics (NASDAQ:CYCN) announced positive topline data from its clinical study of CY6463 for the treatment of Cognitive…
Smith & Nephew Shares Fall On Lower Margins As Cost Headwinds Hit Q2 Profit
Smith & Nephew Plc (NYSE:SNN) reported Q2 revenue of $1.29 billion, up 1.2% on an underlying basis but down 3.1%…
Teladoc Health’s Revised Outlook ‘Implies More Downside’ According To This Analyst
Needham downgraded Teladoc Health Inc (NYSE:TDOC) to Hold following the company’s revised FY22 outlook, which now assumes the low end of…
Gilead’s Biktarvy Demonstrates High Efficacy In HIV/HBV Coinfection Patients
Gilead Sciences Inc (NASDAQ:GILD) announced results reinforcing Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) as a highly efficacious treatment option for HIV, including individuals with…
Why Did Fresenius Medical Care Shares Plunge To 52-Week Low
Shares of kidney dialysis provider Fresenius Medical Care AG & Co (NYSE:FMS) touched a 52-week low after the company cut its…
Why Bausch Health’s Market Cap Was Chopped In Half Thursday: ‘A Near Worst-Case Scenario’
Shares of global health company Bausch Health Companies Inc (NYSE: BHC) are plunging Thursday after a Delaware federal judge issued an oral order on patents related to the company's Xifaxan drug.
Why Shares Of DaVita Are Down Today
Shares of DaVita Inc. (NYSE: DVA) are trading lower today in sympathy Fresenius Medical Care AG & Co (NYSE: FMS), which provided a bearish 2022 outlook and withdrew its 2025 targets.
Daily Biotech Pulse: GSK’s Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion’s Schizophrenia Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours:
AIM ImmunoTech Reports Positive Pilot Study Data From Expanded Access Program Evaluating Ampligen For The Treatment Of Long COVID-19
AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune